United States Health

MapLight (NASDAQ:MPLT) announced that its Phase 2 autism trial of 161 patients missed its primary efficacy endpoint.

Incyte (NASDAQ:INCY) received Japanese regulatory approval for its cancer drug Minjuvi after clinical trials demonstrated response rates up to 71.4%.

Aurora Cannabis (NASDAQ:ACB) reported record global medical cannabis net revenue and adjusted EBITDA for fiscal year 2026, capitalizing on its structural pivot toward high-margin prescription markets in Europe and Australia.

Camurus (NASDAQ:CAMX) announced Monday that Eli Lilly (NYSE:LLY) has formally exercised its option to integrate amylin receptor agonists into the companies' existing cardiometabolic collaboration and license agreement.

Cosmos Health (NASDAQ:COSM) generated record revenue in the first quarter of 2026, driven by sustained distribution gains and market expansions, even as a shifting business mix and operational investments weighed on bottom-line profitability.

CorVel (NASDAQ:CRDL) reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, delivering top-line expansion and a double-digit increase in earnings per share as investments in artificial intelligence and automation optimized clinical workflows.

Lifeway Foods (NASDAQ:LWAY) reported a surge in first-quarter revenue that far outpaced analyst estimates, extending a multi-year growth streak fueled by the mainstreaming of gut-health products.

DarioHealth (NASDAQ:DRIO) posted first-quarter revenue of $5.6 million, a 6.7% increase from the fourth quarter of 2025.

Arbutus Biopharma (NASDAQ:ABUS), a clinical-stage biopharmaceutical company focused on infectious diseases, reported its financial results for the first quarter ended March 31, 2026.

BrainsWay (NASDAQ:BWAY) delivered a powerful first-quarter 2026 performance, marked by a 35% year-over-year revenue increase to $15.5 million.

Dyne Therapeutics (NASDAQ:DYN) ended the first quarter of 2026 with $972.2 million in cash, cash equivalents, and marketable securities.

Warby Parker (NYSE:WRBY) reported first-quarter results for 2026 that exceeded internal guidance across all key financial metrics, signaling resilient demand for its affordable luxury eyewear and integrated vision services.